Literature DB >> 16469784

Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers.

Matthew Townsend1, Ganesh M Shankar, Tapan Mehta, Dominic M Walsh, Dennis J Selkoe.   

Abstract

The accumulation of amyloid beta-protein (Abeta) in brain regions serving memory and cognition is a central pathogenic feature of Alzheimer's disease (AD). We have shown that small soluble oligomers of human Abeta that are naturally secreted by cultured cells inhibit hippocampal long-term potentiation (LTP) in vitro and in vivo and transiently impair the recall of a complex learned behaviour in rats. These results support the hypothesis that diffusible oligomers of Abeta initiate a synaptic dysfunction that may be an early event in AD. We now report detailed electrophysiological analyses that define conditions under which acute application of soluble Abeta inhibits hippocampal synaptic plasticity in wild-type mice. To ascertain which Abeta assemblies contribute to the impairment of LTP, we fractionated oligomers by size-exclusion chromatography and found that Abeta trimers fully inhibit LTP, whereas dimers and tetramers have an intermediate potency. Natural Abeta oligomers are sensitive to heat denaturation, primarily inhibit the induction phase of LTP, and cause a sustained impairment of LTP even after extensive washout. We observed no effects of Abeta oligomers on presynaptic vesicle release. LTP in juvenile mice is resistant to the effects of Abeta oligomers, as is brain-derived-neurotrophic-factor-induced LTP in adult hippocampus. We conclude that specific assemblies, particularly timers, of naturally secreted Abeta oligomers are potent and selective inhibitors of certain forms of hippocampal LTP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469784      PMCID: PMC1779683          DOI: 10.1113/jphysiol.2005.103754

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  56 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  A developmental switch in the signaling cascades for LTP induction.

Authors:  Hiroki Yasuda; Alison L Barth; David Stellwagen; Robert C Malenka
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

Review 4.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

5.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

6.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Kimberley S Gannon; Stephen J Greene; Ronald B DeMattos; Chantal Mathis; Cynthia A DeLong; Su Wu; Xin Wu; David M Holtzman; Steven M Paul
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

7.  Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system.

Authors:  Michael D Ehlers
Journal:  Nat Neurosci       Date:  2003-03       Impact factor: 24.884

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.

Authors:  Rashid Deane; Shi Du Yan; Ram Kumar Submamaryan; Barbara LaRue; Suzana Jovanovic; Elizabeth Hogg; Deborah Welch; Lawrence Manness; Chang Lin; Jin Yu; Hong Zhu; Jorge Ghiso; Blas Frangione; Alan Stern; Ann Marie Schmidt; Don L Armstrong; Bernd Arnold; Birgit Liliensiek; Peter Nawroth; Florence Hofman; Mark Kindy; David Stern; Berislav Zlokovic
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening.

Authors:  Lei Chang; Lara Bakhos; Zhiqiang Wang; Duane L Venton; William L Klein
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more
  241 in total

1.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

3.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 4.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

5.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

6.  Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy.

Authors:  Lyndsey R Powell; Kyle D Dukes; Robin K Lammi
Journal:  Biophys Chem       Date:  2011-09-08       Impact factor: 2.352

7.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

8.  Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools.

Authors:  Suman Nag; Jiji Chen; J Irudayaraj; S Maiti
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

9.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

10.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.